RFCA
CLDX icon

R&F Capital Advisors’s Celldex Therapeutics CLDX Stock Holding History

R&F Capital Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$53K Buy
+973
New +$50.7K 0.01% 645

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

R&F Capital Advisors's CLDX Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Celldex Therapeutics (CLDX) in Q1 2017: 973 shares worth $53K. The stake represents 0.01% of the portfolio and ranks #645 among its holdings.

134 funds tracked by Wall St. Rank hold CLDX as of Q1 2017.

  • R&F Capital Advisors held 973 shares of Celldex Therapeutics worth $53K as of Q1 2017.
  • Celldex Therapeutics was a new R&F Capital Advisors position in Q1 2017.
  • Celldex Therapeutics made up 0.01% of R&F Capital Advisors's portfolio in Q1 2017, its #645 holding.
  • 134 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.